BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
Bone metastases from pancreatic tumors are rare, representing less than 5% of all metastases [ 2 ]. Among these, only three ...
Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on developing ...
(MENAFN- GlobeNewsWire - Nasdaq) – Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE ...
NEW YORK - Bright Minds Biosciences Inc. (NASDAQ:DRUG) will host a conference call and webcast Tuesday at 8:00 AM ET to announce topline results from its Phase 2 trial of BMB-101 in patients with drug ...
Bright Minds Biosciences ( (TSE:DRUG)) has issued an update. On January 5, 2026, Bright Minds Biosciences announced plans to report topline results from its Phase 2 trial of BMB-101 in patients with ...
Activation of TLR7-mediated autophagy increases epileptic susceptibility via reduced KIF5A-dependent GABA A receptor transport in a murine model This study was approved by the Animal Care Committee at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback